Hidden immune hubs in some brain tumors may signal longer survival in glioma patients

Adult-type diffuse gliomas are the most common primary brain tumors and generally respond poorly to immune-based therapies. They are considered immunologically 'cold,' which has limited the success of checkpoint inhibitors and similar approaches. Understanding whether any gliomas mount a real immune response could help identify who might benefit.

This study focused on tertiary lymphoid structures (TLSs), organized clusters of immune cells that form inside tissues outside classical lymph nodes. Using spatial transcriptome and proteome profiling, the team characterized TLSs in a cohort of 642 gliomas.

TLSs were found in about 15% of tumors and were associated with a remodeled perivascular space and spatial redistribution of extracellular matrix components. Three TLS subtypes were defined by cellular composition and immune activity. All lacked classical germinal center architecture, yet certain subtypes showed dynamic immune functions: clonal expansion of T and B cells, generation of IgA+ and IgG+ plasma cells, and dendritic cell-T cell interactions. Patients whose tumors contained TLSs with active immune features had improved overall survival.

The work indicates that a functional adaptive immune response can be detected in a subset of gliomas, challenging the blanket 'cold tumor' label. TLS profiling might eventually help stratify patients and inform immunotherapy trial design.

Caveats: only the abstract was available, so details on cohort composition, tumor grades, molecular subtypes, treatment history, and statistical adjustment are unknown. The survival link is a correlation and does not prove TLSs cause better outcomes or predict response to any therapy. Most gliomas lacked TLSs, so findings apply to a minority.